Akums Drugs & Pharmaceuticals IPO
Akums Drugs & Pharmaceuticals IPO — date, price band, lot size & details 2024
Akums Drugs & Pharmaceuticals listed on 6 Aug 2024 at ₹725, 6.8% above the ₹679 issue price.
Akums Drugs & Pharmaceuticals is a pharmaceutical CDMO making formulations for other drug companies in India and abroad, and also sells branded drugs and APIs. Its total income was Rs 4,212.21 crore in FY2024.
Stock price
Akums Drugs & Pharmaceuticals is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 November.
- Open 30 Jul 2024
- Close 01 Aug 2024
- Allotment 02 Aug 2024
- Refund/credit 05 Aug 2024
- Listing 06 Aug 2024
Issue summary
The terms of the offer, as filed.
| IPO Dates | 30 Jul to 1 Aug, 2024 |
|---|---|
| Price Band | ₹646 – ₹679 |
| Face Value | ₹2 |
| Lot Size | 22 Shares |
| Issue Size | ₹1856.74 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | BSE, NSE |
| Employee Discount | Rs 64.00 per share |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,938 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 22 shares at the ₹679 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 22 | ₹14,938 |
| Retail (max) | 13 | 286 | ₹1,94,194 |
| S-HNI (min) | 14 | 308 | ₹2,09,132 |
| S-HNI (max) | 66 | 1,452 | ₹9,85,908 |
| B-HNI (min) | 67 | 1,474 | ₹10,00,846 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Total income rose from Rs 3,694.52 crore in FY2022 to Rs 4,212.21 crore in FY2024.
- 02Rs 680.99 crore of the issue was fresh capital, with Rs 387.00 crore for repaying debt.
- 03Some units carry European GMP and WHO GMP accreditation, and total income was Rs 3,700.93 crore in FY2023.
- 04Total borrowing fell from Rs 536.97 crore on 31 March 2023 to Rs 491.56 crore on 31 March 2024.
- 05Net worth was Rs 709.50 crore on 31 March 2024.
Risks · 5
- 01Profit was almost nil, at Rs 0.79 crore in FY2024, and the source puts the PAT margin at 0.02%.
- 02The company made a loss of Rs 250.87 crore in FY2022.
- 03The pre-issue P/E was 13580 at the upper band of Rs 679, based on EPS of Rs 0.05.
- 04Rs 1,175.75 crore of the issue was offer for sale, and CDMO income depends on client orders.
- 05Promoters and the promoter group held 82.48% before the issue and 75.29% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Akums Drugs & Pharmaceuticals offer document.
| Metric | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| NET Worth | 709.50 | 717.19 | 621.98 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Akums Drugs & Pharmaceuticals RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Akums Drugs & Pharmaceuticals IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹0.05 | ₹0.05 |
| P/E Ratio (x) | 13,580.00 | 13,580.00 |
| Market Cap at Offer Price (₹ Cr) | ₹10,728.20 | ₹10,728.20 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹679 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹637.37 Cr of the issue is earmarked to named objects.
About the company
It also sells branded pharmaceutical formulations and makes active pharmaceutical ingredients. Its other services include formulation R&D, preparing and filing regulatory dossiers, and testing.
Some of its units are accredited by global agencies such as European GMP, WHO GMP and the US National Sanitation Foundation. Its promoters are Sanjeev Jain, Sandeep Jain and Akums Master Trust.
The IPO was Rs 1,856.74 crore, with Rs 680.99 crore of fresh issue and Rs 1,175.75 crore of offer for sale, mostly by investors, with the two individual promoters also selling. Rs 387.00 crore was planned for repaying borrowings of the company and its subsidiaries.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Akums Drugs & Pharmaceuticals IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Axis Capital
126 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
ICICI Securities
133 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
Ambit Capital
16 issues handledBest listing: Chemcon Speciality Chemicals (+115.0%). Weakest: Metro Brands (-12.6%).
Citigroup Global Markets India Pvt. Ltd
29 issues handledBest listing: Tata Technologies (+140.0%). Weakest: Kalyan Jewellers India (-15.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Akums Drugs & Pharmaceuticals?
The current Grey Market Premium is ₹40, or 6% over the issue price.
What is the Akums Drugs & Pharmaceuticals IPO price band?
₹646 to ₹679, on a face value of ₹2.
When is the allotment?
The basis of allotment is 2 August 2024, with listing on 6 August 2024.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
